Objective: Evaluate Pharmacokinetics and determine the safety of GM-CSF single dose inhalation. Study Design: Pharmacokinetic open study
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
14
Niigata University Med & Dental Hospital
Niigata, Japan
Serum level of Sargramostim
Time frame: 0.5,1,2,4,8,12 and 24 hours after inhalation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.